Department of Neurology, Christian Doppler Klinik, University Hospital Paracelsus Medical University, Salzburg, Austria.
Institute of Public Health, Medical Decision Making, and Health Technology Assessment, University for Health Sciences, Medical Informatics, and Technology, Hall in Tyrol, Austria.
Epilepsia. 2019 Mar;60 Suppl 1:7-21. doi: 10.1111/epi.14458. Epub 2018 Jun 28.
This article reviews the burden of epilepsy in Asia, the challenges faced by people with epilepsy, and the management of epilepsy. Comparison is made with other parts of the world. For this narrative review, data were collected using specified search criteria. Articles investigating the epidemiology of epilepsy, diagnosis, comorbidities and associated mortality, stigmatization, and treatment were included. Epilepsy is a global health care issue affecting up to 70 million people worldwide. Nearly 80% of people with epilepsy live in low- and middle-income countries with limited resources. People with epilepsy are prone to physical and psychological comorbidities, including anxiety and depression, which can negatively impact their quality of life. Furthermore, people with epilepsy are at higher risk of premature death than people without epilepsy. Discrimination or stigmatization of people with epilepsy is common in Asia and can affect their education, work, and marriage opportunities. Access to epilepsy treatment varies throughout Asia. Although highly advanced treatment is available in some countries, up to 90% of people with epilepsy are not adequately treated or are not treated with conventional antiepileptic therapy in resource-limited countries. People in remote areas often do not receive any epilepsy care. First-generation antiepileptic drugs (AEDs) are available, but usually only in urban areas, and second-generation AEDs are not available in all countries. Newer AEDs tend to have more favorable safety profiles than first-generation AEDs and provide options to tailor therapy for individual patients, especially those with comorbidities. Active epilepsy surgery centers are present in some countries, although epilepsy surgery is often underutilized given the number of patients who could benefit. Further epidemiologic research is needed to provide accurate epilepsy data across the Asian region. Coordinated action is warranted to improve access to treatment and care.
本文综述了亚洲癫痫负担、癫痫患者面临的挑战以及癫痫管理,同时与世界其他地区进行了比较。为了进行这篇叙述性综述,使用了特定的搜索标准来收集数据。纳入了调查癫痫流行病学、诊断、合并症和相关死亡率、污名化以及治疗的文章。癫痫是一个全球性的医疗保健问题,影响着全球多达 7000 万人。近 80%的癫痫患者生活在资源有限的低收入和中等收入国家。癫痫患者容易出现身体和心理合并症,包括焦虑和抑郁,这会对他们的生活质量产生负面影响。此外,癫痫患者比非癫痫患者更早死亡的风险更高。在亚洲,癫痫患者经常受到歧视或污名化,这会影响他们的教育、工作和婚姻机会。亚洲各地的癫痫治疗获取情况各不相同。尽管一些国家提供了高度先进的治疗方法,但在资源有限的国家,高达 90%的癫痫患者未得到充分治疗或未接受常规抗癫痫治疗。偏远地区的人们通常无法获得任何癫痫护理。第一代抗癫痫药物(AEDs)可获得,但通常仅在城市地区,并非所有国家都有第二代 AEDs。新型 AEDs通常比第一代 AEDs 具有更有利的安全性,并为针对个体患者的治疗提供了选择,特别是那些有合并症的患者。一些国家存在活跃的癫痫手术中心,但鉴于受益的患者数量,癫痫手术往往未得到充分利用。需要进一步进行流行病学研究,以提供亚洲地区准确的癫痫数据。需要采取协调行动,以改善治疗和护理的获取。